Quality assessment of phase I dose-finding cancer trials: proposal of a checklist (Q33644414)

28 July 2017

title

Quality assessment of phase I dose-finding cancer trials: proposal of a checklist (English)

1 reference

28 July 2017

main subject

phase I clinical trial

0 references

6

Sylvie Chevret

1 reference

28 July 2017

Vincent Levy

3

0 references

author name string

Sarah Zohar

1

1 reference

28 July 2017

Qing Lian

2

1 reference

28 July 2017

Ken Cheung

4

1 reference

28 July 2017

Anastasia Ivanova

5

1 reference

28 July 2017

publication date

1 January 2008

1 reference

28 July 2017

1 reference

28 July 2017

volume

5

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

478-485

1 reference

Experimental designs for phase I and phase I/II dose-finding studies

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Presentation and subsequent publication rates of phase I oncology clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Choice of designs and doses for early phase trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Ethics of phase 1 oncology studies: reexamining the arguments and data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Clinical trial designs for cytostatic agents: are new approaches needed?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

A method for assessing the quality of a randomized control trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Improving the quality of abstract reporting for phase I cancer trials.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Alternate designs for conduct and analysis of phase I cancer trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Phase I clinical trial design in cancer drug development

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

A phase I trial on the ethics of phase I trials

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819819

Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18827040

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A random walk rule for phase I clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18827040

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Escalation, group and A + B designs for dose-finding trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18827040

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1740774508096653

1 reference

28 July 2017

1 reference

28 July 2017

1 reference